Table 3.
Characteristics of the patients stratified according to the KL-6 predictive cut-off for disease progression (N=33)
|
KL-6 <1526 U/mL |
KL-6 ≥1526 U/mL |
p | |
|---|---|---|---|
| (N or mean ± SE) | (N or mean ± SE) | ||
|
Gender (M/F) |
9/10 |
9/5 |
ns* |
|
Age (yrs) |
52±10 |
46±11 |
ns** |
|
Smoking history (yes/no) |
15/4 |
12/2 |
ns* |
|
Clinical course |
|
|
|
| -PAP-related death (yes/no) |
0/19 |
2/12 |
ns* |
| -disease progression (yes/no) |
3/16 |
13/1 |
<0.0001* |
|
Treatment (yes/no) |
6/13 |
12/2 |
0.03* |
| -cumulative number of WLL |
3.5±3 |
7±6.5 |
0.06 |
|
PaO2 (mmHg) |
78±14 |
66±12 |
0.012** |
|
A-aDO2 (mmHg) |
31±12 |
42±14 |
0.023** |
|
VC (% pred) |
88±15 |
72±14 |
0.002** |
|
FEV1 (% pred) |
81±15 |
67±14 |
0.009** |
|
TLC (% pred) |
86±17 |
72±16 |
0.017** |
|
DLCO (% pred) |
70±15 |
42±12 |
<0.0001** |
|
GM-CSF autoantibody (μg/mL) |
44±19 |
55±13 |
ns** |
|
KL-6 (U/mL) |
930±352 |
3934±1756 |
<0.0001** |
|
LDH (IU/L) |
244±78 |
327±109 |
ns** |
| CEA (ng/mL) | 5.5±3.8 | 7.5±6 | ns** |
Unless otherwise indicated, values are expressed as mean ± SD (range).
ns= not significant.
* Fischer´ s exact test.
**Student´ s t-test.